HBV and HCV are the major causes of chronic liver diseases throughout the world, and constitute a major global health risk. There is accumulated evidence that the imbalance of proinflammatory and anti-inflammatory cytokine production may play an important role in the pathogenesis of viral hepatic infections and may influence the clinical outcome and disease progression. This study was undertaken to analyze the circulating levels of Tumor Necrotic Factor (TNF-α) and Th2 cytokine IL-10 in patients infected with Hepatitis B and C virus. The study population consisted of 30 patients with chronic HBV, in addition to other 30 patients with chronic HCV infection were recruited on their first examination at the Al-Kindy General Hospital in Baghdad city. Another 12 healthy individuals with negative hepatitis serology as normal controls were observed. TNF-α level was significantly increased in chronic HBV infected patients compared with normal controls (6.81± 1.25 vs. 5.62± 1.71 pg/ml, p= 0.001). Similarly, the levels of the TNF-α was significantly elevated in HCV patients (8.62± 0.79 pg/ml) after comparison with its level in HBV patients (p= 0.023). Serum levels of Th2 cytokines IL-10 were also elevated in chronic HBV infected patients (25.05± 3.90 pg/ml) and in HCV infected patients (28.07± 3.35 pg/ml)
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death. Therefore, it is critical for researchers to understand molecular biology in greater depth. In several diseases including cancer, abnormal miRNA expression has been linked to apoptosis, proliferation, differentiation, and metastasis. Many miRNAs have been studied in relation to cancer, including miR-122, miR-223, and others. Hepatitis B and C viruses are the most important global risk factors for HCC. This study is intended to test whether serum miRNAs serve as a potential biomarker for both HCC and viral infections HBV and C. The expression of miRNA in 64 serum samples was analyzed by RT-qPCR. Compared to healthy volunteers, HCC patients' sera expre
... Show More
(4)
(2)
Two groups of chronic hepatitis B and C virus patients were divided into Pre-treated patients (25 CHB patients with positive HBs Ag for more than 6 months and 40 CHC patients), and post-treated patients [12 CHB patients (4, 6, and 2 were treated with lamivudine, IFN-? and combination of LMV + IFN-? respectively), and 27 patients for CHC (3, 13 and 11 patients were treated with Ribavirin, IFN-? and combination therapy (RBV+ IFN-?) respectively].These patients were followed up for 6 months. By using ELISA technique, levels of IL-6, IL-10, IFN-? and TNF-? were measured in vivo and in vitro (supernatant of PBMCs stimulated with PHA) and compared with healthy control. The mean level of IL-6, IL-10 and TNF-? in CHB patients showed significant dif
... Show More
Background: five clinical phases were described in patients with chronic (HBV) infection: HBeAg- positive HBV infection, HBeAg- positive chronic HB, HBeAg negative HBV infection, HBeAg-negative CHB and occult HBV infection.
Aim: This study aimed to determine the incidence of the unclassified phase (gray zone) in chronic hepatitis B patients and its significant in the clinical practice.
Patients and methods: The study was conducted retrospectively on 109 patients' who have HBsAg positive for more than 6 months. The data recorded include; HbeAg and anti-HBe Ab, ultrasound of the abdomen, HBV DNA load and alanine aminotransferase (ALT), accordingly; we classify the patients
... Show More
Background: Hepatitis is a disease of the liver caused by the infectious and non-infectious agents.
Patients &methods: A total of 600 blood donors attending blood bank at Baghdad city were included in this study , they were screened by Enzyme Immune sorbent Assay for detection of HBs Ag and anti-HCV ,that confirmed by recombinant immunoblot assay .the possible influence of the various factors on the prevalence was analyze too.
Results: Form the total donors there were 37(6.2%)and 6(1.7%)positive for HBV &HCV respectively .peak prevalence for HBs Ag was noticed in age groups (20-29)years .
Conclusion: Screening blood donors for both HBV and HCV is indispensable for safe blood transfusion. . In gen
(1)
Background: Inhibitor development and HCV are considered the most serious complications of hemophilia treatment. Many factors may increase the risk of complications which include: type of hemophilia, age of the patient, age of onset, duration of the disease, & number of replacement per month. Patients and methods: A descriptive study included 200 patients less than 20 years of age admitted to the Hemophilia Center in Children Welfare Teaching Hospital , medical city in Baghdad , their data ( ag , sex , disease onset and duration , severity of hemophilia ) were collected over 8 months period from 1st January to 31st August 2006. Mixing tests and serology tests for HCV and HBV were performed for all patien
... Show More
(3)
Background Direct-acting antivirals (DAAs) combination therapies from various mechanisms of action and families have been revolutionized the management landscape of chronic hepatitis C virus (HCV). Ombitasvir, paritaprevir with ritonavir (OBV/PTV/r) ± ribavirin (RBV) is approved to treat HCV genotype 4 (GT4) infection. Here, our objective was to delineate the efficacy and safety of OBV/PTV/r plus RBV in treating of Egyptian naïve patients infected with HCV GT4.
Methods a cohort of 100 Egyptian patients infected with HCV GT4 was allocated and administered orally OBV/PTV/r with RBV. The primary endpoint of our study was a sustained virological response (HCV RNA < 12 IU/mL) 12 weeks after the c
... Show More
Abstract: The present study aimed to evaluate calcium, potassium, albumin, protein, creatinine, urea, uric acid levels, and the level of total sialic acid in the sera of patients with chronic renal failure who had been infected with Hepatitis C virus and in the sera of patients with chronic renal failure, and compare them with healthy volunteers. A total of 90 subjects with age 25-55 years, were divided into three groups. G1 represents 30 patients with chronic renal failure who had treated by dialysis and infected with chronic Hepatitis C virus (positive group). G2 represents 30 patients with chronic failure who had been treated by dialysis (negative group), while G3 represents 30 healthy volunteers (control group). The results showed
... Show MoreBackground: Hepatitis B virus (HBV) is one of the major etiological agents causing acute and chronic liver disease worldwide with significant morbidity and mortality. The high genetic variability of HBV is reflected by eight genotypes (A to H), each with a particular geographical prevalence.
Objectives: The study was conducted to find out HBV genotypes in chronic hepatitis B- (CHB) carriers in association with serological markers of HBV.
Methods: This work was carried on from March to, December 2012 in Duhok/Iraq and enrolled 134 HBsAg positive carrier cases. recruited to Central Public Health Lab. Specific primers PCR technique was used to detect HBV genotypes. The carrier cases were screened for markers of HBV infection by Enzyme
(5)
Objective(s): This study aims to assess health related quality of life among Iraqi patients with chronic viral hepatitis
B and C also to find out the relationship between health related quality of life and patients demographic
characteristic and to design a new measurement scale for assessing QoL among viral hepatitis B and C patients
which can be suitable to be adopted for Iraqi patients
Methodology: A descriptive quantitative study is carried out at Gastroenterology and Hepatology Teaching
Hospital from February, 1st, 2011 to August 30th 2011, Anon probability (purposive sample) of (100) chronic viral
hepatitis B and C persons , who were clients of Gastroenterology and Hepatology Teaching Hospital / outpatient
clin
Chronic viral hepatitis is an important health problem in the world, where hepatitis B virus (HBV) or hepatitis C virus (HCV) infections are the main causes of liver insufficiency. The study included 100 blood samples from patients with chronic viral hepatitis, fifty of them with HBV infection and 50 with HCV infection. Twenty apparently healthy age and gender matched subjects were included as a control group. Out of the 50 patients with HBV, 36(72%) were males and 14(28%) were females. Thirty two (64%) patients with HCV were males and 18(36%) were females. The mean age for HBV patients was 36.9 ± 15.8 year and for HCV patients it was 39.9 ±14.2 year. The results of the liver function tests showed no significant differ
... Show More